ZD1839 (Iressa)

DRUG4 trials

Sponsors

Weill Medical College of Cornell University, Sidney Kimmel Cancer Center at Thomas Jefferson University, AstraZeneca, University of Chicago

Conditions

Head and Neck CancerNon Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Carcinoma (NSCLC)

Phase 1

Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer

TerminatedNCT00195078

Weill Medical College of Cornell UniversityHead and Neck Cancer

Start: 2004-04-30End: 2006-09-30Target: 29Updated: 2007-07-20

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

CompletedNCT00328562

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNon-Small Cell Lung Carcinoma (NSCLC)

Start: 2003-12-31End: 2010-09-30Updated: 2025-05-04

Phase 2

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

CompletedNCT01185158

University of ChicagoHead and Neck Cancer

Start: 2002-05-31End: 2010-11-30Updated: 2023-11-29

Unknown Phase

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

AstraZenecaNon Small Cell Lung Cancer (NSCLC)

Updated: 2018-09-13